InvestorsHub Logo

2times2

03/27/15 6:35 PM

#499 RE: BiotechValues #498

correct!...SP does not reflect revenue and balance sheet at all, esp. since it was kept at the current level through buyback and Tan's purchases.
As soon as institutional and overseas investors find the confidence back (starting with this Q4 report) the SP will steadily climb. I see the overall potential and situation comfortable enough to add until June/Q1'15 ER and hold past that before any flipping might be useful or portions might be cashed out for gains. I see the stock in the 2nd half of 2015 rise to the original IPO levels.